Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Psoriatic arthritis: state of the art review
Laura C. Coates, Philip Helliwell
Clinical Medicine (2017) Vol. 17, Iss. 1, pp. 65-70
Open Access | Times Cited: 273

Showing 1-25 of 273 citing articles:

Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies
Farzad Alinaghi, Monika Calov, Lars Erik Kristensen, et al.
Journal of the American Academy of Dermatology (2018) Vol. 80, Iss. 1, pp. 251-265.e19
Open Access | Times Cited: 503
Psoriasis Prevalence in Adults in the United States
April W. Armstrong, Manan D. Mehta, Clayton W. Schupp, et al.
JAMA Dermatology (2021) Vol. 157, Iss. 8, pp. 940-940
Open Access | Times Cited: 337
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
Iain B. McInnes, Frank Behrens, Philip J. Mease, et al.
The Lancet (2020) Vol. 395, Iss. 10235, pp. 1496-1505
Closed Access | Times Cited: 237
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
Xenofon Baraliakos, Laure Gossec, Effie Pournara, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 5, pp. 582-590
Open Access | Times Cited: 144
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
Laura C. Coates, Robert Landewé, Iain B. McInnes, et al.
RMD Open (2024) Vol. 10, Iss. 1, pp. e003855-e003855
Open Access | Times Cited: 18
The epidemiology of psoriatic arthritis: A literature review
Paras Karmacharya, Rikesh Chakradhar, Alexis Ogdie
Best Practice & Research Clinical Rheumatology (2021) Vol. 35, Iss. 2, pp. 101692-101692
Closed Access | Times Cited: 85
Axial involvement in psoriatic arthritis: An update for rheumatologists
Denis Poddubnyy, Deepak R. Jadon, Filip Van den Bosch, et al.
Seminars in Arthritis and Rheumatism (2021) Vol. 51, Iss. 4, pp. 880-887
Open Access | Times Cited: 77
Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes
Iain B. McInnes, L. Sawyer, Kristen Markus, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002074-e002074
Open Access | Times Cited: 48
Microneedles as a momentous platform for psoriasis therapy and diagnosis: A state-of-the-art review
B.H. Jaswanth Gowda, Mohammed Gulzar Ahmed, Umme Hani, et al.
International Journal of Pharmaceutics (2023) Vol. 632, pp. 122591-122591
Closed Access | Times Cited: 39
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study
Christopher T. Ritchlin, Laura C. Coates, Iain B. McInnes, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 11, pp. 1404-1414
Open Access | Times Cited: 28
Obesity mediates the association between psoriasis and diabetes incidence: a population-based study
Zuojiao Xu, Kaihua Ma, Yujia Zhai, et al.
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 1
Early Use of Beneficial Biological Therapy on Younger Psoriasis Patients: Could a ‘Step‐Down’ Therapy Approach Be More Effective?
Yasmina Behlock, Céline Dandoy, Fabienne Willaert, et al.
International Journal of Dermatology (2025)
Open Access | Times Cited: 1
Axial psoriatic arthritis: An update for dermatologists
Alice B. Gottlieb, Joseph F. Merola
Journal of the American Academy of Dermatology (2020) Vol. 84, Iss. 1, pp. 92-101
Open Access | Times Cited: 65
Psoriatic Arthritis: What is Happening at the Joint?
Jennifer Belasco, Nathan Wei
Rheumatology and Therapy (2019) Vol. 6, Iss. 3, pp. 305-315
Open Access | Times Cited: 57
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
Philip J. Mease, Iain B. McInnes, Lai‐Shan Tam, et al.
Lara D. Veeken (2021) Vol. 60, Iss. 5, pp. 2109-2121
Open Access | Times Cited: 56
Overview of the molecular determinants contributing to the expression of Psoriasis and Psoriatic Arthritis phenotypes
Valerio Caputo, Claudia Strafella, Andrea Termine, et al.
Journal of Cellular and Molecular Medicine (2020) Vol. 24, Iss. 23, pp. 13554-13563
Open Access | Times Cited: 55
Diagnostic Delay in Psoriatic Arthritis: A Population-based Study
Paras Karmacharya, Kerry Wright, Sara J. Achenbach, et al.
The Journal of Rheumatology (2021) Vol. 48, Iss. 9, pp. 1410-1416
Open Access | Times Cited: 43
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study
Laura C. Coates, Iain B. McInnes, Joseph F. Merola, et al.
Arthritis & Rheumatology (2022) Vol. 74, Iss. 12, pp. 1959-1970
Open Access | Times Cited: 29
Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study
Xiaomei Leng, Wei Lin, Shixue Liu, et al.
RMD Open (2023) Vol. 9, Iss. 1, pp. e002559-e002559
Open Access | Times Cited: 20
Mendelian Randomization Studies in Psoriasis and Psoriatic Arthritis: A Systematic Review
Joy Q. Jin, Kareem G. Elhage, Riley K. Spencer, et al.
Journal of Investigative Dermatology (2023) Vol. 143, Iss. 5, pp. 762-776.e3
Open Access | Times Cited: 20
Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey
April W. Armstrong, Barbra Bohannan, S. Mburu, et al.
Dermatology (2023) Vol. 239, Iss. 4, pp. 621-634
Open Access | Times Cited: 20
Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs
Angela McArdle, Stephen R. Pennington, Oliver FitzGerald
Clinical Reviews in Allergy & Immunology (2017) Vol. 55, Iss. 3, pp. 271-294
Closed Access | Times Cited: 57
Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials
Boni E. Elewski, Phoebe Rich, Edward Lain, et al.
Journal of Dermatological Treatment (2020) Vol. 33, Iss. 1, pp. 261-265
Closed Access | Times Cited: 48
Quality of healthcare information on YouTube: psoriatic arthritis
Mustafa Erkut Önder, Orhan Zengin
Zeitschrift für Rheumatologie (2021) Vol. 82, Iss. S1, pp. 30-37
Open Access | Times Cited: 41
Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis
Valerio Caputo, Claudia Strafella, Terenzio Cosio, et al.
Genes (2021) Vol. 12, Iss. 9, pp. 1398-1398
Open Access | Times Cited: 40
Page 1 - Next Page

Scroll to top